Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Cabozantinib reduces tumour burden in Phase II neurofibromatosis trial

europeanpharmaceuticalreviewJanuary 18, 2021

Tag: cabozantinib , NF1 , Tumor

PharmaSources Customer Service